Andros Pharmaceuticals Co (ROCO:6917) Total Equity: NT$515.72 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6917 Andros Pharmaceuticals Co Ltd ROCO:6917
41 GF Score
Price NT$34.50
GF Value NT$165.02
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Andros Pharmaceuticals Co Total Equity?

Andros Pharmaceuticals Co ROCO:6917 -3.09% 41 Total Equity is NT$515.72 Mil as of Dec. 2025. GuruFocus rates ROCO:6917 with a GF Score™ of 41/100 and a GF Value™ of NT$165.02 (Possible Value Trap). The stock has 4 warning signs investors should review.

Andros Pharmaceuticals Co's total equity for the quarter that ended in Dec. 2025 was NT$515.72 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Andros Pharmaceuticals Co Total Equity Historical Data

* Premium members only.

The historical data trend for Andros Pharmaceuticals Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Andros Pharmaceuticals Co Total Equity Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 68.66 279.48 471.11 394.17 515.72

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 471.11 438.12 394.17 357.37 515.72
ROCO:6917
41GF Score
Andros Pharmaceuticals Co Ltd ROCO:6917
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Andros Pharmaceuticals Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Andros Pharmaceuticals Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=558.972-43.253
=515.72

Andros Pharmaceuticals Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=558.972-43.253
=515.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$515.72 Mil mean?
Andros Pharmaceuticals Co (ROCO:6917) has a Total Equity of NT$515.72 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Andros Pharmaceuticals Co and its competitors.
Is Andros Pharmaceuticals Co's Total Equity too high?
Andros Pharmaceuticals Co's current Total Equity is NT$515.72 Mil. Overall, Andros Pharmaceuticals Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's Total Equity compare to VRTX and REGN?
Andros Pharmaceuticals Co's Total Equity of NT$515.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Andros Pharmaceuticals Co and its competitors. Andros Pharmaceuticals Co's current Total Equity is NT$515.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.02, compared to a current price of NT$34.50 — trading 79.1% below its estimated fair value. The current Total Equity is NT$515.72 Mil. Andros Pharmaceuticals Co's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current Total Equity is NT$515.72 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?

Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$34.50 is trading 79.1% below its estimated GF Value™ of NT$165.02. GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for ROCO:6917:

  • Total Equity: NT$515.72 Mil
  • GF Value™: NT$165.02 vs. price of NT$34.50 (79.1% below fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Andros Pharmaceuticals Co Business Description

Address No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
41GF Score

Get the complete analysis for ROCO:6917

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.50
Price
NT$165.02
GF Value